Breast Conservation Surgery Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Local treatment of ipsilateral breast cancer recurrences: comparison of alternative therapeutic options
Magy Onkol. 2024 Mar 14;68(1):86-88. Epub 2024 Jan 30.ABSTRACTWe compared the clinical outcomes of second breast conserving therapy (2ndBCT) versus salvage mastectomy (sMT) for the treatment of ipsilateral breast tumour recurrences (IBTR). 195 patients who presented with an IBTR after previous breast conserving treatment were salvaged either with re-excision and perioperative interstitial brachytherapy (n=39) or sMT (n=156). A total dose of 5×4.4Gy was delivered to the tumour bed, on 3 consecutive days. The median follow-up time was 59 and 56 months. During follow-up 4 (10.2%) and 28 (17.9%) second local recurrences occur...
Source: Magyar Onkologia - March 14, 2024 Category: Cancer & Oncology Authors: Viktor Smanyk ó Source Type: research

Clinical practicality and patient performance for surface-guided automated VMAT gating for DIBH breast cancer radiotherapy
Radiotherapy (RT) is applied after breast-conserving surgery to enhance local control and overall survival in breast cancer patients [1]. As a consequence and particularly among patients with left-sided breast cancer, radiation dose is incidental partially delivered to the heart and lungs, which is known to increase the risk of cardiovascular and lung disease [2,3]. Advanced radiation techniques like volumetric modulated arc therapy (VMAT) have been developed to deliver more precise and conformal doses to better spare the heart and lungs [4 –6]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 14, 2024 Category: Radiology Authors: Sophie Huijskens, Patrick Granton, Kimm Fremeijer, Cynthia van Wanrooij, Kirsten Offereins-van Harten, Suzanne Schouwenaars-van den Beemd, Mischa Hoogeman, Margriet G.A. Sattler, Joan Penninkhof Tags: Original Article Source Type: research

Cancers, Vol. 16, Pages 1138: Ten-Year Results of Accelerated Partial-Breast Irradiation with Interstitial Multicatheter Brachytherapy after Breast-Conserving Surgery for Low-Risk Early Breast Cancer
dro C. Lara Patients with an early carcinoma of the breast are commonly treated by breast-conserving surgery (BCS) and postoperative radiotherapy. Partial-breast irradiation has gained acceptance in the last few years. Between December 2008 and December 2017, 182 low-risk breast cancer patients treated by BCS in the four university hospitals of the province of Las Palmas and treated with APBI using interstitial multicatheter brachytherapy were included in this study. After a mean follow-up for survivors of 10 years, the treatment was shown to be safe, as no severe acute/late toxicity (grade &ge; 3) was observed...
Source: Cancers - March 13, 2024 Category: Cancer & Oncology Authors: Nieves G. Rodr íguez-Ibarria Beatriz Pinar Laura Garc ía Auxiliadora Cabez ón Dolores Rey-Baltar Juan Ignacio Rodr íguez-Melcón Marta Lloret Pedro C. Lara Tags: Article Source Type: research

Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: The Oncologist)
Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research

Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: Cancer Control)
Source: Cancer Control - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research